Cutera (NASDAQ:CUTR) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Cutera (NASDAQ:CUTR) in a report issued on Tuesday morning. The firm issued a sell rating on the medical device company’s stock.

Several other analysts have also issued reports on the stock. Piper Sandler reiterated a “neutral” rating and issued a $1.00 target price (down previously from $3.00) on shares of Cutera in a research note on Friday, August 9th. Stephens decreased their price objective on shares of Cutera from $10.00 to $5.00 and set an “overweight” rating for the company in a research note on Friday, August 9th.

Cutera Stock Up 16.6 %

CUTR stock opened at $0.46 on Tuesday. The firm has a market capitalization of $9.23 million, a PE ratio of -0.07 and a beta of 1.35. Cutera has a twelve month low of $0.28 and a twelve month high of $4.97. The stock’s 50 day moving average is $0.59 and its 200-day moving average is $1.12.

Hedge Funds Weigh In On Cutera

Several institutional investors have recently added to or reduced their stakes in CUTR. Bayesian Capital Management LP purchased a new position in Cutera in the first quarter valued at about $33,000. Ground Swell Capital LLC purchased a new position in Cutera in the second quarter valued at approximately $37,000. Squarepoint Ops LLC grew its holdings in Cutera by 164.5% during the second quarter. Squarepoint Ops LLC now owns 113,964 shares of the medical device company’s stock valued at $172,000 after purchasing an additional 70,870 shares during the period. Finally, Bank of Montreal Can increased its position in Cutera by 14.2% in the second quarter. Bank of Montreal Can now owns 282,704 shares of the medical device company’s stock worth $455,000 after buying an additional 35,248 shares during the last quarter. Institutional investors own 90.70% of the company’s stock.

Cutera Company Profile

Cutera, Inc provides aesthetic and dermatology solutions for medical practitioners worldwide. It develops, manufactures, and markets energy-based product platforms for medical practitioners; and distributes third-party manufactured skincare products. The company provides AviClear for the treatment of mild, moderate, and severe inflammatory acne vulgaris; Secret PRO, a device that utilizes fractional CO2 for skin resurfacing and radio frequency (RF) microneedling for skin revitalization; truFlex, a bio-electrical muscle stimulation device designs to strengthen, firm and tone the abdomen, buttocks, and thighs; and excel V/V+, a vascular and benign pigmented lesion treatment platform.